Biophytis (EPA:ALBPS)

BRIEF

published on 03/26/2026 at 07:35, 14 days 10 hours ago

Biophytis and LynxKite Feature at NVIDIA GTC Conference

Biophytis Drug Discovery NVIDIA GTC AI In Longevity AlphaFold Database
REGULATED PRESS RELEASE

published on 03/26/2026 at 07:30, 14 days 10 hours ago

BIOPHYTIS-LYNXKITE ALLIANCE INVITED TO NVIDIA CONFERENCE: UNLEASHING AI TO REVOLUTIONIZE LONGEVITY
Biophytis SA participated in NVIDIA GTC conference to advance AI-driven drug discovery in longevity in collaboration with LynxKite Technologies and Nebius, positioning them at the forefront of innovation in the $1.5 trillion longevity market

Longevity Biophytis SA AI-driven Drug Discovery NVIDIA GTC Conference LynxKite Technologies
PRESS RELEASE

published on 03/26/2026 at 07:29, 14 days 11 hours ago

BIOPHYTIS-LYNXKITE ALLIANCE INVITED TO NVIDIA CONFERENCE: UNLEASHING AI TO REVOLUTIONIZE LONGEVITY
Biophytis announces participation at NVIDIA GTC conference, showcasing AI-driven drug discovery collaborations with LynxKite and Nebius to revolutionize longevity innovation

Biophytis AI-driven Drug Discovery LynxKite NVIDIA GTC Longevity Innovation
BRIEF

published on 03/13/2026 at 07:35, 27 days 10 hours ago

Biophytis Unveils Obesity and Sarcopenia Programs at ICFSR Conference

Biophytis Clinical Research Sarcopenia ICFSR Conference Obesity
REGULATED PRESS RELEASE

published on 03/13/2026 at 07:30, 27 days 10 hours ago

BIOPHYTIS PRESENTS ITS DEVELOPMENT PROGRAMS IN OBESITY AND SARCOPENIA AT THE ICFSR CONFERENCE
Biophytis presents its development programs in obesity and sarcopenia at the ICFSR conference, showcasing BIO101 in obesity and SARA program in sarcopenia

Biophytis Clinical Research Sarcopenia ICFSR Conference Obesity
PRESS RELEASE

published on 03/13/2026 at 07:29, 27 days 11 hours ago

BIOPHYTIS PRESENTS ITS DEVELOPMENT PROGRAMS IN OBESITY AND SARCOPENIA AT THE ICFSR CONFERENCE
Biophytis presents its obesity and sarcopenia development programs at ICFSR Conference, highlighting clinical trials on healthy longevity and innovative therapies

Biophytis Clinical Research Sarcopenia ICFSR Conference Obesity
BRIEF

published on 03/12/2026 at 09:42, 28 days 8 hours ago

Biophytis raises €2 million in funding

Biophytis Fundraising Joint Venture Debt Repayment Sarcopenia
PRESS RELEASE

published on 03/12/2026 at 09:37, 28 days 8 hours ago

BIOPHYTIS ANNOUNCES COMPLETION OF OVER €2.0 MILLION CAPITAL INCREASE AND THE REPAYMENT OF ALL VARIABLE PRICE CONVERTIBLE DEBT
Biophytis completes a €2.0 million capital increase, repays variable price convertible debt, and plans to focus on clinical development in sarcopenia and obesity. Key investors include Alumni Capital Management, Bigger Capital, and Hexagon Capital Fund

Biophytis Capital Increase Sarcopenia Obesity Convertible Debt
BRIEF

published on 03/12/2026 at 07:35, 28 days 10 hours ago

Biophytis Expands AI Partnership with LynxKite for Longevity Drug Discovery

Biophytis Drug Discovery Longevity Sarcopenia LynxKite
REGULATED PRESS RELEASE

published on 03/12/2026 at 07:30, 28 days 10 hours ago

Biophytis-LynxKite Alliance Expands to Turbocharge AI-driven drug discovery for next generation longevity therapeutics
Biophytis and LynxKite form alliance to boost AI-driven drug discovery for longevity therapies, targeting sarcopenia and AMD

Biophytis Sarcopenia AI-driven Drug Discovery LynxKite Longevity Therapeutics

Published on 04/09/2026 at 16:00, 2 hours 29 minutes ago

Banff Half Marathon Completes 2025 Emissions Assessment, Supporting Climate Action with Karbon-X
Published on 04/09/2026 at 14:40, 3 hours 49 minutes ago

Silver X Delivers Production Growth During the First Quarter of 2026
Published on 04/09/2026 at 14:00, 4 hours 29 minutes ago

Orogen Royalties Announces Mineral Reserve and Resource Update on Producing Ermitaño Royalty
Published on 04/09/2026 at 13:30, 4 hours 59 minutes ago

Datametrex Receives $6M Purchase Order for Data Centre from Fortune 500 Conglomerate
Published on 04/09/2026 at 13:30, 4 hours 59 minutes ago

ESGold Advances Toward Production and Exploration Drilling as Mill Buildout Progresses in Parallel

View all ACCESSWIRE

Published on 04/09/2026 at 18:15, 14 minutes ago

REPLY: Launch of a share buyback program for a maximum number of 3,607,950 shares
Published on 04/09/2026 at 15:59, 2 hours 30 minutes ago

Cairn Homes Plc: Holding(s) in Company
Published on 04/09/2026 at 15:57, 2 hours 32 minutes ago

Cairn Homes Plc: Holding(s) in Company
Published on 04/09/2026 at 15:40, 2 hours 49 minutes ago

Form 8.3 - The Vanguard Group, Inc.: LondonMetric Property plc
Published on 04/09/2026 at 15:39, 2 hours 50 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Schroders plc

View all EQS

Published on 04/09/2026 at 17:35, 54 minutes ago

SUEZ - FY 2025
Published on 04/09/2026 at 15:57, 2 hours 32 minutes ago

Filing of CNP Assurances SA 2025 universal registration document and 2025 Solvency and Financial Condition Reports
Published on 04/09/2026 at 07:00, 11 hours 29 minutes ago

bioMérieux Unveils its BIOFIRE® SPOTFIRE® Molecular Testing Solution for the Pharmaceutical Industry, Redefining Rapid Mycoplasma Testing
Published on 04/08/2026 at 18:02, 1 day ago

Publication of the 2025 Universal Registration Document
Published on 04/08/2026 at 17:45, 1 day ago

DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS

View all LES ECHOS COMFI WIRE

News